- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02590809
Hypertrophic Cardiomyopathy Symptom Release by BX1514M (Light-CARMIDO)
February 9, 2022 updated by: University Hospital, Bordeaux
Hypertrophic cardiomyopathy (HCM) is the most frequent genetic cardiac disease characterized by an asymmetric hypertrophic.
In two third of patients, an obstruction to blood ejection is observed within the left ventricle which is named left ventricular outflow tract obstruction (LVOTO).
This phenomenon can occur at rest or during exercise and is associated with symptoms such as dyspnea, dizziness or chest pain that can significantly limit day life adaptation.
To now, medical or interventional treatments such as betablocacker, calcium blockers or septal alcoholisation or surgery present with a limited efficiency.
Recent studies from investigators group revealed new concepts about the role of venous return to the LVOTO.
Therefore the investigators hypothesis that BX1514M generating a venous vascular constriction, could improve symptoms of HCM patients by reducing LVOTO.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bordeaux, France
- CHU de Bordeaux
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with a typical or atypical hypertrophic cardiomyopathy (HCM) confirmed by imaging modalities (echo and MRI) and/or genetic tests or a relative history of HCM
- Left ventricular obstruction during exercise on treadmill (above 50 mmHg)
- Positive response to leg lifting test (obstruction reduction above 20 mmHg) at rest or in early recovery phase
- Daily symptoms as shortness of breath during exercise (NYHA2-3), non coronary chest pain, dizziness
- Correct ultrasound windows quality
- Sinus rhythm
- Optimal medical treatment
- For women, pregnancy test or contraception
- Written consent form obtained
Exclusion Criteria:
- Previous treatment by BX1514M
- Extra-cardiac pathology with life expectancy below than 1 year
- No capability of consent form written
- Pregnancy women
- Secondary hypertension hypertrophy, secondary valvular disease hypertrophy
- Permanent atrial fibrillation
- Severe ventricular arrhythmia without Implantable Cardioverter Defibrillator (ICD)
- Severe coronary disease
- Severe non stabilized hypertension
- Severe cardiopathy (ejection fraction below 40% or demonstrated elevated end diastolic pressure or pulmonary pressure above 60 mmHg)
- Bradycardia
- Narrow angle glaucoma
- Vascular prethrombotic diseases
- Vascular spams
- Thyrotoxicosis
- Pheochromocytoma
- Severe renal failure (<30ml/mn)
- Patients at risk of urinary retention secondary to prostatic severe disease
- Raynaud's disease
- Non selective Monoamine Oxidase Inhibitors (MAOIs), iproniazid, nialamide or ephedrine, methylphenidate, phenylephrine, pseudoephedrine or digitalic
- Procedures modifying the peripheral venous return
- Participation to other research protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group
20 patients
|
X mg x 3 /day of BX1514M for 15 days.
Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
Walk distance test during 6 minutes
|
Placebo Comparator: Placebo group
20 patients
|
Walk distance test during 6 minutes
Placebo will be given for 30 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline at day 15 of covered distance during the 6 minutes walk distance test (6MWT)
Time Frame: Day 15
|
In meters
|
Day 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Covered distance during the 6 minutes walk distance test (6MWT)
Time Frame: Day 30
|
In meters
|
Day 30
|
Exercise echocardiography with measures of blood pressures in the rest and in the effort
Time Frame: Day 1, day 15, day 30
|
Day 1, day 15, day 30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Stéphane LAFITTE, Pr, University Hospital, Bordeaux
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 7, 2015
Primary Completion (Actual)
July 6, 2016
Study Completion (Actual)
July 6, 2016
Study Registration Dates
First Submitted
October 27, 2015
First Submitted That Met QC Criteria
October 28, 2015
First Posted (Estimate)
October 29, 2015
Study Record Updates
Last Update Posted (Actual)
February 10, 2022
Last Update Submitted That Met QC Criteria
February 9, 2022
Last Verified
February 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2015/14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertrophic Cardiomyopathy
-
French Cardiology SocietyCompleted1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | 2- Obstructive Hypertrophic Cardiomyopathy | 3- Non Obstructive Hypertrophic CardiomyopathyFrance
-
University of Sao PauloCompletedNon-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyBrazil
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR)Enrolling by invitationCardiomyopathies | Hypertrophic Cardiomyopathy | Hypertrophic Obstructive Cardiomyopathy | Familial Hypertrophic CardiomyopathyCanada
-
Bristol-Myers SquibbActive, not recruitingHypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyDenmark, United States, Belgium, Czechia, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
-
Yonsei UniversityCompletedFamilial Hypertrophic CardiomyopathyKorea, Republic of
-
Hangzhou Valgen Medtech Co., LtdNot yet recruitingObstructive Hypertrophic CardiomyopathyChina
-
China National Center for Cardiovascular DiseasesNot yet recruitingObstructive Hypertrophic Cardiomyopathy
-
Bristol-Myers SquibbNot yet recruitingObstructive Hypertrophic CardiomyopathyKorea, Republic of
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.RecruitingObstructive Hypertrophic CardiomyopathyChina
-
Xiang WeiRecruitingNonobstructive Hypertrophic CardiomyopathyChina
Clinical Trials on Treatment BX1514M
-
PfizerCompleted
-
PfizerCompleted
-
Chiesi Farmaceutici S.p.A.Completed
-
Gilead SciencesCompletedChronic Lymphocytic LeukemiaUnited States
-
PfizerCompleted
-
JW PharmaceuticalCompletedHealthyKorea, Republic of
-
AstraZenecaParexelCompleted
-
PfizerCompletedHealthy VolunteersUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingIntra-articular Fracture of the Mandibular CondyleFrance
-
New Mexico VA Healthcare SystemCompletedPost Traumatic Stress DisorderUnited States